International Stem Cell Begins Pre-Clinical Testing Of Its Parthenogenetic Stem Cells For Treatment Of Retinal Disease

International Stem Cell Corporation (OTCBB: ISCO) has created layered human tissue from its unique parthenogenetic stem cells and transplanted this tissue into animals in pre-clinical trials to establish a potential new treatment for human retinal diseases, such as macular degeneration or retinitis pigmentosa. “Intact layers of retinal progenitor cells have been shown to restore lost visual responses in several retinal degeneration rodent models,” said Dr.

More: continued here

Filed under: Eye Health on January 16th, 2009